Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 4/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.49 |
| ▸ | OXTR | P30559 | 4/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | VHL | P40337 | 1/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19270360 | 1.00 | FFAR2 (0.50) | FFAR2AVPR1AOXTRAVPR2PIK3CD | |
| SCHEMBL24314080 | 1.00 | FFAR2 (0.50) | FFAR2AVPR1AOXTRAVPR2PIK3CD | |
| SCHEMBL29449381 | 1.00 | FFAR2 (0.50) | FFAR2AVPR1AOXTRAVPR2PIK3CD | |
| SCHEMBL31156208 | 0.87 | AVPR1A (0.49) | FFAR2AVPR1AOXTRAVPR2PIK3CD | |
| SCHEMBL28754781 | 0.87 | PIK3CD (0.44) | AVPR1AOXTRAVPR2PIK3CDVHL | |
| SCHEMBL4424510 | 0.86 | PIK3CD (0.52) | FFAR2PIK3CDVHLSLC6A7ATM | |
| SCHEMBL9028119 | 0.83 | PIK3CD (0.61) | PIK3CDVHLATM | |
| SCHEMBL10469223 | 0.83 | PIK3CD (0.61) | PIK3CDVHLATM | |
| SCHEMBL9028110 | 0.83 | PIK3CD (0.61) | PIK3CDVHLATM | |
| SCHEMBL2459843 | 0.83 | PIK3CD (0.61) | PIK3CDVHLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2023-03-30 | — | — | US | disclosed |
| EP-4129979-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ObsEva S.A. (CH) | 2023-02-08 | — | — | EP | disclosed |
| US-11419851-B2 | Oral formulations of pyrrolidine derivatives | ObsEva S.A. (CH) | 2022-08-23 | — | — | US | disclosed |
| US-11312683-B2 | Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists | ObsEva S.A. (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| WO-2015036160-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN / VASOPRESSIN V1a RECEPTORS ANTAGONISTS | ObsEva S.A. (CH) | 2015-03-19 | — | — | WO | disclosed |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2015-03-12 | — | — | US | disclosed |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2015-03-12 | — | — | US | disclosed |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2015-03-12 | — | — | US | disclosed |
| EP-2845850-A1 | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists | ObsEva S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| EP-1725526-B1 | METHOD FOR PREPARING PYRROLIDINE OXIMES | SERONO LAB (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312683-B2 | Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists | OXTR, AVPR1A, AVPR2 | FFAR2 826/4885AVPR1A 2/4885OXTR 1/4885 |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | FFAR2 989/4885AVPR1A 2/4885OXTR 1/4885 |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | FFAR2 3352/4885AVPR1A 2299/4885OXTR 76/4885 |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | FFAR2 711/4885AVPR1A 2/4885OXTR 1/4885 |
| US-11419851-B2 | Oral formulations of pyrrolidine derivatives | KDM5A, KDM5C, PGF | FFAR2 3399/4885AVPR1A 2409/4885OXTR 70/4885 |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | PPOX, PGF, OXTR | FFAR2 4051/4885AVPR1A 398/4885OXTR 3/4885 |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | AVPR1A, OXTR, AVPR2 | FFAR2 1040/4885AVPR1A 1/4885OXTR 2/4885 |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | FFAR2 3352/4885AVPR1A 2299/4885OXTR 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.